Anal cancer: Current standards in care and recent changes in practice

CA Cancer Journal for Clinicians

Volumn 65, Issue 2, 2015, Pages 139-162

  Shridhar, Ravi ^a   Shibata, David ^a   Chan, Emily ^b   Thomas, Charles R ^c  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b VANDERBILT UNIVERSITY   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

abdominoperineal resection; anal cancer; brachytherapy; chemoradiation; chemotherapy; intensity modulated radiation therapy; quality of life; salvage therapy; sentinel lymph node biopsy; squamous cell carcinoma

Indexed keywords

ANTIRETROVIRUS AGENT; BULKING AGENT; CAPECITABINE; CARBOPLATIN; CETUXIMAB; CISPLATIN; ERLOTINIB; ESTROGEN; FLUOROPYRIMIDINE; FLUOROURACIL; IMIQUIMOD; LOPERAMIDE; MITOMYCIN; OXALIPLATIN; PACLITAXEL; PANITUMUMAB; PLACEBO; SILDENAFIL; WART VIRUS VACCINE;

ANAL CANAL; ANEMIA; ANUS CANCER; ANUS CARCINOMA; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER SURGERY; CHEMORADIOTHERAPY; CLINICAL PRACTICE; CONDYLOMA; CONTINUOUS INFUSION; DIARRHEA; DRUG DOSE REDUCTION; DYSPLASIA; ELECTROLYTE DISTURBANCE; GASTROINTESTINAL SYMPTOM; GENITAL SYSTEM DISEASE; HUMAN; INFECTION; LIVER METASTASIS; METASTASIS; MUCOSA INFLAMMATION; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PATIENT CARE; PERIPHERAL NEUROPATHY; PRACTICE GUIDELINE; PRECANCER; PRIORITY JOURNAL; PUBLICATION; REVIEW; SALVAGE THERAPY; SQUAMOUS CELL CARCINOMA; SQUAMOUS CELL LUNG CARCINOMA; TINNITUS; VOMITING; ADENOCARCINOMA; ANUS NEOPLASMS; CANCER STAGING; CARCINOMA, SQUAMOUS CELL; COMPLICATION; EPIDEMIOLOGY; EVIDENCE BASED MEDICINE; HEALTH CARE QUALITY; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; MORTALITY; PREVALENCE; PROCEDURES; PROGNOSIS; RISK FACTOR; SEXUAL BEHAVIOR; STATISTICS AND NUMERICAL DATA; SURVIVAL RATE; TREATMENT FAILURE; TREATMENT OUTCOME; UNITED STATES;

ADENOCARCINOMA; ANUS NEOPLASMS; CARCINOMA, SQUAMOUS CELL; CHEMORADIOTHERAPY; EVIDENCE-BASED MEDICINE; GUIDELINES AS TOPIC; HIV INFECTIONS; HUMANS; INCIDENCE; NEOPLASM STAGING; PREVALENCE; PROGNOSIS; RISK FACTORS; SALVAGE THERAPY; SEXUAL BEHAVIOR; STANDARD OF CARE; SURVIVAL RATE; TREATMENT FAILURE; TREATMENT OUTCOME; UNITED STATES;

EID: 84924238243     PISSN: 00079235     EISSN: 15424863     Source Type: Journal    
DOI: 10.3322/caac.21259     Document Type: Review

References (180)

1. Siegel R, Ma J, Zou Z, Jemal A,. Cancer statistics, 2014. CA Cancer J Clin. 2014; 64: 9-29.
2. Nelson RA, Levine AM, Bernstein L, Smith DD, Lai LL,. Changing patterns of anal canal carcinoma in the United States. J Clin Oncol. 2013; 31: 1569-1575.
3. Klas JV, Rothenberger DA, Wong WD, Madoff RD,. Malignant tumors of the anal canal: the spectrum of disease, treatment, and outcomes. Cancer. 1999; 85: 1686-1693.
4. Moore HG, Guillem JG,. Anal neoplasms. Surg Clin North Am. 2002; 82: 1233-1251.
5. Darragh TM, Colgan TJ, Cox JT, et al. The Lower Anogenital Squamous Terminology Standardization Project for HPV-Associated Lesions: background and consensus recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology. Arch Pathol Lab Med. 2012; 136: 1266-1297.
6. Berry JM, Jay N, Cranston RD, et al. Progression of anal high-grade squamous intraepithelial lesions to invasive anal cancer among HIV-infected men who have sex with men. Int J Cancer. 2014; 134: 1147-1155.
7. National Comprehensive Cancer Network (NCCN). NCCN Guidelines for Anal Carcinoma. Version 2.2014. Fort Washington, PA: NCCN; 2014.
8. Uronis HE, Bendell JC,. Anal cancer: an overview. Oncologist. 2007; 12: 524-534.
9. Daling JR, Weiss NS, Hislop TG, et al. Sexual practices, sexually transmitted diseases, and the incidence of anal cancer. N Engl J Med. 1987; 317: 973-977.
10. Daling JR, Madeleine MM, Johnson LG, et al. Human papillomavirus, smoking, and sexual practices in the etiology of anal cancer. Cancer. 2004; 101: 270-280.
11. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Human papillomaviruses. IARC Monogr Eval Carcinog Risks Hum. 2007; 90: 1-636.
12. Frisch M, Glimelius B, van den Brule AJ, et al. Sexually transmitted infection as a cause of anal cancer. N Engl J Med. 1997; 337: 1350-1358.
13. Steinau M, Unger ER, Hernandez BY, et al. Human papillomavirus prevalence in invasive anal cancers in the United States before vaccine introduction. J Low Genit Tract Dis. 2013; 17: 397-403.
14. Zandberg DP, Bhargava R, Badin S, Cullen KJ,. The role of human papillomavirus in nongenital cancers. CA Cancer J Clin. 2013; 63: 57-81.
15. Penn I,. Cancers of the anogenital region in renal transplant recipients. Analysis of 65 cases. Cancer. 1986; 58: 611-616.
16. Sillman FH, Sedlis A,. Anogenital papillomavirus infection and neoplasia in immunodeficient women: an update. Dermatol Clin. 1991; 9: 353-369.
17. Palefsky JM, Holly EA, Hogeboom CJ, et al. Virologic, immunologic, and clinical parameters in the incidence and progression of anal squamous intraepithelial lesions in HIV-positive and HIV-negative homosexual men. J Acquir Immune Defic Syndr Hum Retrovirol. 1998; 17: 314-319.
18. Palefsky JM, Holly EA, Ralston ML, et al. Anal squamous intraepithelial lesions in HIV-positive and HIV-negative homosexual and bisexual men: prevalence and risk factors. J Acquir Immune Defic Syndr Hum Retrovirol. 1998; 17: 320-326.
19. Grat M, Grat K, Holowko W, et al. Initial prevalence of anal human papilloma virus infection in liver transplant recipients. Transplant Int. 2014; 27: 816-823.
20. Roka S, Rasoul-Rockenschaub S, Roka J, Kirnbauer R, Muhlbacher F, Salat A,. Prevalence of anal HPV infection in solid-organ transplant patients prior to immunosuppression. Transplant Int. 2004; 17: 366-369.
21. Machalek DA, Poynten M, Jin F, et al. Anal human papillomavirus infection and associated neoplastic lesions in men who have sex with men: a systematic review and meta-analysis. Lancet Oncol. 2012; 13: 487-500.
22. Shiels MS, Pfeiffer RM, Chaturvedi AK, Kreimer AR, Engels EA,. Impact of the HIV epidemic on the incidence rates of anal cancer in the United States. J Natl Cancer Inst. 2012; 104: 1591-1598.
23. Silverberg MJ, Lau B, Justice AC, et al. Risk of anal cancer in HIV-infected and HIV-uninfected individuals in North America. Clin Infect Dis. 2012; 54: 1026-1034.
24. Guiguet M, Boue F, Cadranel J, et al. Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study. Lancet Oncol. 2009; 10: 1152-1159.
25. Piketty C, Selinger-Leneman H, Bouvier AM, et al. Incidence of HIV-related anal cancer remains increased despite long-term combined antiretroviral treatment: results from the French hospital database on HIV. J Clin Oncol. 2012; 30: 4360-4366.
26. Chiao EY, Hartman CM, El-Serag HB, Giordano TP,. The impact of HIV viral control on the incidence of HIV-associated anal cancer. J Acquir Immune Defic Syndr. 2013; 63: 631-638.
27. Bower M, Powles T, Newsom-Davis T, et al. HIV-associated anal cancer: has highly active antiretroviral therapy reduced the incidence or improved the outcome? J Acquir Immune Defic Syndr. 2004; 37: 1563-1565.
28. Chao C, Leyden WA, Xu L, et al. Exposure to antiretroviral therapy and risk of cancer in HIV-infected persons. AIDS. 2012; 26: 2223-2231.
29. Daling JR, Sherman KJ, Hislop TG, et al. Cigarette smoking and the risk of anogenital cancer. Am J Epidemiol. 1992; 135: 180-189.
30. Wells JS, Holstad MM, Thomas T, Bruner DW,. An integrative review of guidelines for anal cancer screening in HIV-infected persons. AIDS Patient Care STDS. 2014; 28: 350-357.
31. Ortoski RA, Kell CS,. Anal cancer and screening guidelines for human papillomavirus in men. J Am Osteopath Assoc. 2011; 111 (3 suppl 2): S35-S43.
32. Pineda CE, Berry JM, Jay N, Palefsky JM, Welton ML,. High resolution anoscopy in the planned staged treatment of anal squamous intraepithelial lesions in HIV-negative patients. J Gastrointest Surg. 2007; 11: 1410-1415; discussion 1415-1416.
33. Pineda CE, Berry JM, Jay N, Palefsky JM, Welton ML,. High-resolution anoscopy targeted surgical destruction of anal high-grade squamous intraepithelial lesions: a ten-year experience. Dis Colon Rectum. 2008; 51: 829-835, 2008; discussion 835-837.
34. Lam JU, Rebolj M, Dugue PA, Bonde J, von Euler-Chelpin M, Lynge E,. Condom use in prevention of human papillomavirus infections and cervical neoplasia: systematic review of longitudinal studies. J Med Screen. 2014; 21: 38-50.
35. Giuliano AR, Palefsky JM, Goldstone S, et al. Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males. N Engl J Med. 2011; 364: 401-411.
36. Palefsky JM, Giuliano AR, Goldstone S, et al. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N Engl J Med. 2011; 365: 1576-1585.
37. Bosman FT, Carneiro F, Hruban RH, Theise ND, eds. World Health Organization Classification of Human Tumours of the Digestive System, Volume 3. 4th ed. Lyon, France: IARC Press; 2010.
38. Palefsky JM, Cranston RD,. Anal squamous intraepithelial lesions: diagnosis, screening, prevention, and treatment [serial online; published online 2014]. UpToDate.com. Accessed on December 10, 2014.
39. Miller EJ, Quan SH, Thaler HT,. Treatment of squamous cell carcinoma of the anal canal. Cancer. 1991; 67: 2038-2041.
40. Tanum G, Tveit K, Karlsen KO,. Diagnosis of anal carcinoma-doctor's finger still the best? Oncology. 1991; 48: 383-386.
41. Solomon D, Davey D, Kurman R, et al. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA. 2002; 287: 2114-2119.
42. Palefsky JM, Holly EA,. Molecular virology and epidemiology of human papillomavirus and cervical cancer. Cancer Epidemiol Biomarkers Prev. 1995; 4: 415-428.
43. Bilimoria KY, Bentrem DJ, Rock CE, Stewart AK, Ko CY, Halverson A,. Outcomes and prognostic factors for squamous-cell carcinoma of the anal canal: analysis of patients from the National Cancer Data Base. Dis Colon Rectum. 2009; 52: 624-631.
44. Wade DS, Herrera L, Castillo NB, Petrelli NJ,. Metastases to the lymph nodes in epidermoid carcinoma of the anal canal studied by a clearing technique. Surg Gynecol Obstet. 1989; 169: 238-242.
45. Davey P, Saibil EA, Wong R,. Bipedal lymphography in the management of carcinoma of the anal canal. Br J Radiol. 1996; 69: 632-635.
46. Gerard JP, Chapet O, Samiei F, et al. Management of inguinal lymph node metastases in patients with carcinoma of the anal canal: experience in a series of 270 patients treated in Lyon and review of the literature. Cancer. 2001; 92: 77-84.
47. Papillon J, Montbarbon JF,. Epidermoid carcinoma of the anal canal. A series of 276 cases. Dis Colon Rectum. 1987; 30: 324-333.
48. Ortholan C, Resbeut M, Hannoun-Levi JM, et al. Anal canal cancer: management of inguinal nodes and benefit of prophylactic inguinal irradiation (CORS-03 Study). Int J Radiat Oncol Biol Phys. 2012; 82: 1988-1995.
49. Gunderson LL, Moughan J, Ajani JA, et al. Anal carcinoma: impact of TN category of disease on survival, disease relapse, and colostomy failure in US Gastrointestinal Intergroup RTOG 98-11 phase 3 trial. Int J Radiat Oncol Biol Phys. 2013; 87: 638-645.
50. Glynne-Jones R, Kadalayil L, Meadows HM, et al. Tumour- and treatment-related colostomy rates following mitomycin C or cisplatin chemoradiation with or without maintenance chemotherapy in squamous cell carcinoma of the anus in the ACT II trial. Ann Oncol. 2014; 25: 1616-1622.
51. Ajani JA, Winter KA, Gunderson LL, et al. Prognostic factors derived from a prospective database dictate clinical biology of anal cancer: the intergroup trial (RTOG 98-11). Cancer. 2010; 116: 4007-4013.
52. Bartelink H, Roelofsen F, Eschwege F, et al. Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups. J Clin Oncol. 1997; 15: 2040-2049.
53. Linam JM, Chand RR, Broudy VC, et al. Evaluation of the impact of HIV serostatus, tobacco smoking and CD4 counts on epidermoid anal cancer survival. Int J STD AIDS. 2012; 23: 77-82.
54. Glynne-Jones R, Meadows H, Wan S, et al. EXTRA-a multicenter phase II study of chemoradiation using a 5 day per week oral regimen of capecitabine and intravenous mitomycin C in anal cancer. Int J Radiat Oncol Biol Phys. 2008; 72: 119-126.
55. Saranovic D, Barisic G, Krivokapic Z, Masulovic D, Djuric-Stefanovic A,. Endoanal ultrasound evaluation of anorectal diseases and disorders: technique, indications, results and limitations. Eur J Radiol. 2007; 61: 480-489.
56. Roach SC, Hulse PA, Moulding FJ, Wilson R, Carrington BM,. Magnetic resonance imaging of anal cancer. Clin Radiol. 2005; 60: 1111-1119.
57. Cotter SE, Grigsby PW, Siegel BA, et al. FDG-PET/CT in the evaluation of anal carcinoma. Int J Radiat Oncol Biol Phys. 2006; 65: 720-725.
58. Winton E, Heriot AG, Ng M, et al. The impact of 18-fluorodeoxyglucose positron emission tomography on the staging, management and outcome of anal cancer. Br J Cancer. 2009; 100: 693-700.
59. De Nardi P, Carvello M, Staudacher C,. New approach to anal cancer: individualized therapy based on sentinel lymph node biopsy. World J Gastroenterol. 2012; 18: 6349-6356.
60. Mistrangelo DM, Bello M, Cassoni P, et al. Value of staging squamous cell carcinoma of the anal margin and canal using the sentinel lymph node procedure: an update of the series and a review of the literature. Br J Cancer. 2013; 108: 527-532.
61. Mistrangelo M, Pelosi E, Bello M, et al. Comparison of positron emission tomography scanning and sentinel node biopsy in the detection of inguinal node metastases in patients with anal cancer. Int J Radiat Oncol Biol Phys. 2010; 77: 73-78.
62. de Jong JS, Beukema JC, van Dam GM, Slart R, Lemstra C, Wiggers T,. Limited value of staging squamous cell carcinoma of the anal margin and canal using the sentinel lymph node procedure: a prospective study with long-term follow-up. Ann Surg Oncol. 2010; 17: 2656-2662.
63. Gutzmer R, Kaspari M, Vogelbruch M, et al. Successful treatment of anogenital Bowen's disease with the immunomodulator imiquimod, and monitoring of therapy by DNA image cytometry. Br J Dermatol. 2002; 147: 160-165.
64. Ulrich C, Bichel J, Euvrard S, et al. Topical immunomodulation under systemic immunosuppression: results of a multicentre, randomized, placebo-controlled safety and efficacy study of imiquimod 5% cream for the treatment of actinic keratoses in kidney, heart, and liver transplant patients. Br J Dermatol. 2007; 157 (suppl 2): 25-31.
65. Wieland U, Brockmeyer NH, Weissenborn SJ, et al. Imiquimod treatment of anal intraepithelial neoplasia in HIV-positive men. Arch Dermatol. 2006; 142: 1438-1444.
66. Richel O, Wieland U, de Vries HJ, et al. Topical 5-fluorouracil treatment of anal intraepithelial neoplasia in human immunodeficiency virus-positive men. Br J Dermatol. 2010; 163: 1301-1307.
67. Richel O, de Vries HJ, van Noesel CJ, Dijkgraaf MG, Prins JM,. Comparison of imiquimod, topical fluorouracil, and electrocautery for the treatment of anal intraepithelial neoplasia in HIV-positive men who have sex with men: an open-label, randomised controlled trial. Lancet Oncol. 2013; 14: 346-353.
68. Goldstone SE, Johnstone AA, Moshier EL,. Long-term outcome of ablation of anal high-grade squamous intraepithelial lesions: recurrence and incidence of cancer. Dis Colon Rectum. 2014; 57: 316-323.
69. Goldstone RN, Goldstone AB, Russ J, Goldstone SE,. Long-term follow-up of infrared coagulator ablation of anal high-grade dysplasia in men who have sex with men. Dis Colon Rectum. 2011; 54: 1284-1292.
70. Boman BM, Moertel CG, O'Connell MJ, et al. Carcinoma of the anal canal. A clinical and pathologic study of 188 cases. Cancer. 1984; 54: 114-125.
71. Frost DB, Richards PC, Montague ED, Giacco GG, Martin RG,. Epidermoid cancer of the anorectum. Cancer. 1984; 53: 1285-1293.
72. Wexler A, Berson AM, Goldstone SE, et al. Invasive anal squamous-cell carcinoma in the HIV-positive patient: outcome in the era of highly active antiretroviral therapy. Dis Colon Rectum. 2008; 51: 73-81.
73. Nigro ND, Vaitkevicius VK, Considine B Jr,. Combined therapy for cancer of the anal canal: a preliminary report. Dis Colon Rectum. 1974; 17: 354-356.
74. Leichman L, Nigro N, Vaitkevicius VK, et al. Cancer of the anal canal. Model for preoperative adjuvant combined modality therapy. Am J Med. 1985; 78: 211-215.
75. Arnott S, Cunningham J, Gallagher J, UK Co-ordinating Committee on Cancer Research Anal Cancer Trial Working Party. Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. Lancet. 1996; 348: 1049-1054.
76. Northover J, Glynne-Jones R, Sebag-Montefiore D, et al. Chemoradiation for the treatment of epidermoid anal cancer: 13-year follow-up of the first randomised UKCCCR Anal Cancer Trial (ACT I). Br J Cancer. 2010; 102: 1123-1128.
77. Flam M, John M, Pajak TF, et al. Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study. J Clin Oncol. 1996; 14: 2527-2539.
78. Ajani JA, Winter KA, Gunderson LL, et al. Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial. JAMA. 2008; 299: 1914-1921.
79. Gunderson LL, Winter KA, Ajani JA, et al. Long-term update of US GI intergroup RTOG 98-11 phase III trial for anal carcinoma: survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil/mitomycin versus fluorouracil/cisplatin. J Clin Oncol. 2012; 30: 4344-4351.
80. James RD, Glynne-Jones R, Meadows HM, et al. Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial. Lancet Oncol. 2013; 14: 516-524.
81. Peiffert D, Tournier-Rangeard L, Gerard JP, et al. Induction chemotherapy and dose intensification of the radiation boost in locally advanced anal canal carcinoma: final analysis of the randomized UNICANCER ACCORD 03 trial. J Clin Oncol. 2012; 30: 1941-1948.
82. Chakravarthy AB, Catalano PJ, Martenson JA, et al. Long-term follow-up of a phase II trial of high-dose radiation with concurrent 5-fluorouracil and cisplatin in patients with anal cancer (ECOG E4292). Int J Radiat Oncol Biol Phys. 2011; 81: e607-e613.
83. Doci R, Zucali R, La Monica G, et al. Primary chemoradiation therapy with fluorouracil and cisplatin for cancer of the anus: results in 35 consecutive patients. J Clin Oncol. 1996; 14: 3121-3125.
84. Mendelsohn J, Baselga J,. The EGF receptor family as targets for cancer therapy. Oncogene. 2000; 19: 6550-6565.
85. Prewett MC, Hooper AT, Bassi R, Ellis LM, Waksal HW, Hicklin DJ,. Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts. Clin Cancer Res. 2002; 8: 994-1003.
86. Van Damme N, Deron P, Van Roy N, et al. Epidermal growth factor receptor and K-RAS status in two cohorts of squamous cell carcinomas [serial online]. BMC Cancer. 2010; 10: 189.
87. Olivatto LO, Vieira FM, Pereira BV, et al. Phase 1 study of cetuximab in combination with 5-fluorouracil, cisplatin, and radiotherapy in patients with locally advanced anal canal carcinoma. Cancer. 2013; 119: 2973-2980.
88. Deutsch E, Lemanski C, Paris E, et al. Cetuximab plus radiochemotherapy in locally advanced anal cancer: interim results of the French multicenter phase II trial ACCORD16 [abstract]. J Clin Oncol. 2011; 29 (7 suppl). Abstract 4098.
89. Bosset JF, Roelofsen F, Morgan DA, et al. Shortened irradiation scheme, continuous infusion of 5-fluorouracil and fractionation of mitomycin C in locally advanced anal carcinomas. Results of a phase II study of the European Organization for Research and Treatment of Cancer. Radiotherapy and Gastrointestinal Cooperative Groups. Eur J Cancer. 2003; 39: 45-51.
90. Eng C, Chang G, Das P, et al. Phase II study of capecitabine and oxaliplatin with concurrent radiation therapy (XELOX-XRT) for squamous cell carcinoma of the anal canal [abstract]. J Clin Oncol. 2009; 27: 15(suppl). Abstract 4116.
91. Matzinger O, Roelofsen F, Mineur L, et al. Mitomycin C with continuous fluorouracil or with cisplatin in combination with radiotherapy for locally advanced anal cancer (European Organisation for Research and Treatment of Cancer phase II study 22011-40014). Eur J Cancer. 2009; 45: 2782-2791.
92. Chiao EY, Giordano TP, Richardson P, El-Serag HB,. Human immunodeficiency virus-associated squamous cell cancer of the anus: epidemiology and outcomes in the highly active antiretroviral therapy era. J Clin Oncol. 2008; 26: 474-479.
93. Seo Y, Kinsella MT, Reynolds HL, Chipman G, Remick SC, Kinsella TJ,. Outcomes of chemoradiotherapy with 5-fluorouracil and mitomycin C for anal cancer in immunocompetent versus immunodeficient patients. Int J Radiat Oncol Biol Phys. 2009; 75: 143-149.
94. Oehler-Janne C, Huguet F, Provencher S, et al. HIV-specific differences in outcome of squamous cell carcinoma of the anal canal: a multicentric cohort study of HIV-positive patients receiving highly active antiretroviral therapy. J Clin Oncol. 2008; 26: 2550-2557.
95. Klencke BJ, Palefsky JM,. Anal cancer: an HIV-associated cancer. Hematol Oncol Clin North Am. 2003; 17: 859-872.
96. Hoffman R, Welton ML, Klencke B, Weinberg V, Krieg R,. The significance of pretreatment CD4 count on the outcome and treatment tolerance of HIV-positive patients with anal cancer. Int J Radiat Oncol Biol Phys. 1999; 44: 127-131.
97. Fraunholz I, Weiss C, Eberlein K, Haberl A, Rodel C,. Concurrent chemoradiotherapy with 5-fluorouracil and mitomycin C for invasive anal carcinoma in human immunodeficiency virus-positive patients receiving highly active antiretroviral therapy. Int J Radiat Oncol Biol Phys. 2010; 76: 1425-1432.
98. Cummings BJ, Keane TJ, O'Sullivan B, Wong CS, Catton CN,. Epidermoid anal cancer: treatment by radiation alone or by radiation and 5-fluorouracil with and without mitomycin C. Int J Radiat Oncol Biol Phys. 1991; 21: 1115-1125.
99. Glynne-Jones R, Nilsson PJ, Aschele C, et al. Anal cancer: ESMO-ESSO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up. Radiother Oncol. 2014; 111: 330-339.
100. Chuong M, Freilich J, Hoffe S, et al. Intensity-modulated radiation therapy versus conventional radiation therapy for squamous cell carcinoma of the anal canal. Gastrointest Cancer Res. 2013; 6: 39-45.
101. Kachnic LA, Winter K, Myerson RJ, et al. RTOG 0529: a phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal. Int J Radiat Oncol Biol Phys. 2013; 86: 27-33.
102. Bazan JG, Hara W, Hsu A, et al. Intensity-modulated radiation therapy versus conventional radiation therapy for squamous cell carcinoma of the anal canal. Cancer. 2011; 117: 3342-3351.
103. Dewas CV, Maingon P, Dalban C, et al. Does gap-free intensity modulated chemoradiation therapy provide a greater clinical benefit than 3D conformal chemoradiation in patients with anal cancer [serial online]? Radiat Oncol. 2012; 7: 201.
104. Milano MT, Jani AB, Farrey KJ, Rash C, Heimann R, Chmura SJ,. Intensity-modulated radiation therapy (IMRT) in the treatment of anal cancer: toxicity and clinical outcome. Int J Radiat Oncol Biol Phys. 2005; 63: 354-361.
105. Salama JK, Mell LK, Schomas DA, et al. Concurrent chemotherapy and intensity-modulated radiation therapy for anal canal cancer patients: a multicenter experience. J Clin Oncol. 2007; 25: 4581-4586.
106. Pepek JM, Willett CG, Wu QJ, Yoo S, Clough RW, Czito BG,. Intensity-modulated radiation therapy for anal malignancies: a preliminary toxicity and disease outcomes analysis. Int J Radiat Oncol Biol Phys. 2010; 78: 1413-1419.
107. Call JA, Haddock MG, Quevedo JF, Larson DW, Miller RC,. Intensity-modulated radiotherapy for squamous cell carcinoma of the anal canal: efficacy of a low daily dose to clinically negative regions [serial online]. Radiat Oncol. 2011; 6: 134.
108. Chuong MD, Hoffe SE, Weber J, et al. Outcomes of anal cancer treated with definitive IMRT-based chemoradiation. J Radiat Oncol. 2012; 1: 165-172.
109. Kachnic LA, Tsai HK, Coen JJ, et al. Dose-painted intensity-modulated radiation therapy for anal cancer: a multi-institutional report of acute toxicity and response to therapy. Int J Radiat Oncol Biol Phys. 2012; 82: 153-158.
110. DeFoe SG, Beriwal S, Jones H, et al. Concurrent chemotherapy and intensity-modulated radiation therapy for anal carcinoma-clinical outcomes in a large National Cancer Institute-designated integrated cancer centre network. Clin Oncol (R Coll Radiol). 2012; 24: 424-431.
111. Vieillot S, Fenoglietto P, Lemanski C, et al. IMRT for locally advanced anal cancer: clinical experience of the Montpellier Cancer Center [serial online]. Radiat Oncol. 2012; 7: 45.
112. Mitchell MP, Abboud M, Eng C, et al. Intensity-modulated radiation therapy with concurrent chemotherapy for anal cancer: outcomes and toxicity. Am J Clin Oncol. 2014; 37: 461-466.
113. Herman JM, Thomas CR Jr,. RTOG 0529: Intensity modulated radiation therapy and anal cancer, a step in the right direction? Int J Radiat Oncol Biol Phys. 2013; 86: 8-10.
114. Dasgupta T, Rothenstein D, Chou JF, et al. Intensity-modulated radiotherapy vs conventional radiotherapy in the treatment of anal squamous cell carcinoma: a propensity score analysis. Radiother Oncol. 2013; 107: 189-194.
115. Saarilahti K, Arponen P, Vaalavirta L, Tenhunen M,. The effect of intensity-modulated radiotherapy and high dose rate brachytherapy on acute and late radiotherapy-related adverse events following chemoradiotherapy of anal cancer. Radiother Oncol. 2008; 87: 383-390.
116. Papillon J, Montbarbon JF, Gerard JP, Chassard JL, Ardiet JM,. Interstitial curietherapy in the conservative treatment of anal and rectal cancers. Int J Radiat Oncol Biol Phys. 1989; 17: 1161-1169.
117. Berger C, Felix-Faure C, Chauvet B, et al. Conservative treatment of anal canal carcinoma with external radiotherapy and interstitial brachytherapy, with or without chemotherapy: long-term results [article in French]. Cancer Radiother. 1999; 3: 461-467.
118. Hwang JM, Rao AR, Cosmatos HA, et al. Treatment of T3 and T4 anal carcinoma with combined chemoradiation and interstitial 192Ir implantation: a 10-year experience. Brachytherapy. 2004; 3: 95-100.
119. Lestrade L, De Bari B, Montbarbon X, Pommier P, Carrie C,. Radiochemotherapy and brachytherapy could be the standard treatment for anal canal cancer in elderly patients? A retrospective single-centre analysis [serial online]. Med Oncol. 2013; 30: 402.
120. Chuong MD, Fernandez DC, Shridhar R, et al. High-dose-rate endorectal brachytherapy for locally advanced rectal cancer in previously irradiated patients. Brachytherapy. 2013; 12: 457-462.
121. Gabriel WB,. Squamous-cell carcinoma of the anus and anal canal: an analysis of 55 cases: (Section of Proctology). Proc R Soc Med. 1941; 34: 139-160.
122. Dalby JE, Pointon RS,. The treatment of anal carcinoma by interstitial irradiation. AJR Am J Roentgenol Radium Ther Nucl Med. 1961; 85: 515-520.
123. Oehler-Janne C, Seifert B, Lutolf UM, Studer G, Glanzmann C, Ciernik IF,. Clinical outcome after treatment with a brachytherapy boost versus external beam boost for anal carcinoma. Brachytherapy. 2007; 6: 218-226.
124. Moureau-Zabotto L, Ortholan C, Hannoun-Levi JM, et al. Role of brachytherapy in the boost management of anal carcinoma with node involvement (CORS-03 study). Int J Radiat Oncol Biol Phys. 2013; 85: e135-e142.
125. Matthews JH, Burmeister BH, Borg M, et al. T1-2 anal carcinoma requires elective inguinal radiation treatment-the results of Trans Tasman Radiation Oncology Group study TROG 99.02. Radiother Oncol. 2011; 98: 93-98.
126. Zilli T, Betz M, Bieri S, et al. Elective inguinal node irradiation in early-stage T2N0 anal cancer: prognostic impact on locoregional control. Int J Radiat Oncol Biol Phys. 2013; 87: 60-66.
127. Mullen JT, Rodriguez-Bigas MA, Chang GJ, et al. Results of surgical salvage after failed chemoradiation therapy for epidermoid carcinoma of the anal canal. Ann Surg Oncol. 2007; 14: 478-483.
128. Schiller DE, Cummings BJ, Rai S, et al. Outcomes of salvage surgery for squamous cell carcinoma of the anal canal. Ann Surg Oncol. 2007; 14: 2780-2789.
129. Renehan AG, Saunders MP, Schofield PF, O'Dwyer ST,. Patterns of local disease failure and outcome after salvage surgery in patients with anal cancer. Br J Surg. 2005; 92: 605-614.
130. Eeson G, Foo M, Harrow S, McGregor G, Hay J,. Outcomes of salvage surgery for epidermoid carcinoma of the anus following failed combined modality treatment. Am J Surg. 2011; 201: 628-633.
131. Sunesen KG, Buntzen S, Tei T, Lindegaard JC, Norgaard M, Laurberg S,. Perineal healing and survival after anal cancer salvage surgery: 10-year experience with primary perineal reconstruction using the vertical rectus abdominis myocutaneous (VRAM) flap. Ann Surg Oncol. 2009; 16: 68-77.
132. Bakx R, van Lanschot JJ, Zoetmulder FA,. Inferiorly based rectus abdominis myocutaneous flaps in surgical oncology: indications, technique, and experience in 37 patients. J Surg Oncol. 2004; 85: 93-97.
133. Horner M, Ries L, Krapcho M, et al, eds. SEER Cancer Statistics Review, 1975-2006. Bethesda, MD: National Cancer Institute; 2009.
134. Ryan D, Willett CG,. Anal cancer. In:, Steele GD, Phillips TL, Chabner BA, eds; Willett CG, series ed. American Cancer Society Atlas of Clinical Oncology: Cancer of the Lower Gastrointestinal Tract. Hamilton, Ontario: BC Decker Inc.; 2001: 196-213.
135. Cummings BJ,. Metastatic anal cancer: the search for cure. Onkologie. 2006; 29 (1-2): 5-6.
136. Eng C, Pathak P,. Treatment options in metastatic squamous cell carcinoma of the anal canal. Curr Treat Options Oncol. 2008; 9 (4-6): 400-407.
137. James R, Wan S, Glynne-Jones R, et al. A randomized trial of chemoradiation using mitomycin or cisplatin, with or without maintenance cisplatin/5FU in squamous cell carcinoma of the anus (ACT II) [abstract]. J Clin Oncol. 2009; 27 (18 suppl). Abstract LBA4009.
138. Faivre C, Rougier P, Ducreux M, et al. 5-Fluorouracile and cisplatinum combination chemotherapy for metastatic squamous-cell anal cancer [article in French]. Bull Cancer. 1999; 86: 861-865.
139. Ajani JA, Carrasco CH, Jackson DE, Wallace S,. Combination of cisplatin plus fluoropyrimidine chemotherapy effective against liver metastases from carcinoma of the anal canal. Am J Med. 1989; 87: 221-224.
140. Pathak P, King B, Ohinata A, et al. The treatment of metastatic squamous cell carcinoma (SCCA) of the anal canal: a single institution experience [abstract]. J Clin Oncol. 2008; 26 (15 suppl). Abstract A352.
141. Kim R, Byer J, Fulp WJ, Mahipal A, Dinwoodie W, Shibata D,. Carboplatin and paclitaxel treatment is effective in advanced anal cancer. Oncology. 2014; 87: 125-132.
142. Hainsworth JD, Burris HA, 3rd, Meluch AA, Baker MN, Morrissey LH, Greco FA,. Paclitaxel, carboplatin, and long-term continuous infusion of 5-fluorouracil in the treatment of advanced squamous and other selected carcinomas. Cancer. 2001; 92: 642-649.
143. Chao C, Goldberg M, Hoffman JP,. Surgical salvage therapy: abdominoperineal resection for recurrent anal carcinoma, metastasectomy of recurrent colorectal cancer, and esophagectomy after combined chemoradiation. Curr Opin Oncol. 2000; 12: 353-356.
144. Pawlik TM, Gleisner AL, Bauer TW, et al. Liver-directed surgery for metastatic squamous cell carcinoma to the liver: results of a multi-center analysis. Ann Surg Oncol. 2007; 14: 2807-2816.
145. Das P, Bhatia S, Eng C, et al. Predictors and patterns of recurrence after definitive chemoradiation for anal cancer. Int J Radiat Oncol Biol Phys. 2007; 68: 794-800.
146. Wright JL, Patil SM, Temple LK, Minsky BD, Saltz LB, Goodman KA,. Squamous cell carcinoma of the anal canal: patterns and predictors of failure and implications for intensity-modulated radiation treatment planning. Int J Radiat Oncol Biol Phys. 2010; 78: 1064-1072.
147. Ng M, Leong T, Chander S, et al. Australasian Gastrointestinal Trials Group (AGITG) contouring atlas and planning guidelines for intensity-modulated radiotherapy in anal cancer. Int J Radiat Oncol Biol Phys. 2012; 83: 1455-1462.
148. Widder J, Kastenberger R, Fercher E, et al. Radiation dose associated with local control in advanced anal cancer: retrospective analysis of 129 patients. Radiother Oncol. 2008; 87: 367-375.
149. Hughes LL, Rich TA, Delclos L, Ajani JA, Martin RG,. Radiotherapy for anal cancer: experience from 1979-1987. Int J Radiat Oncol Biol Phys. 1989; 17: 1153-1160.
150. Huang K, Haas-Kogan D, Weinberg V, Krieg R,. Higher radiation dose with a shorter treatment duration improves outcome for locally advanced carcinoma of anal canal. World J Gastroenterol. 2007; 13: 895-900.
151. Ferrigno R, Nakamura RA, Dos Santos Novaes PE, et al. Radiochemotherapy in the conservative treatment of anal canal carcinoma: retrospective analysis of results and radiation dose effectiveness. Int J Radiat Oncol Biol Phys. 2005; 61: 1136-1142.
152. Konski A, Garcia M Jr, John M, et al. Evaluation of planned treatment breaks during radiation therapy for anal cancer: update of RTOG 92-08. Int J Radiat Oncol Biol Phys. 2008; 72: 114-118.
153. Ben-Josef E, Moughan J, Ajani JA, et al. Impact of overall treatment time on survival and local control in patients with anal cancer: a pooled data analysis of Radiation Therapy Oncology Group trials 87-04 and 98-11. J Clin Oncol. 2010; 28: 5061-5066.
154. Roohipour R, Patil S, Goodman KA, et al. Squamous-cell carcinoma of the anal canal: predictors of treatment outcome. Dis Colon Rectum. 2008; 51: 147-153.
155. Pocard M, Tiret E, Nugent K, Dehni N, Parc R,. Results of salvage abdominoperineal resection for anal cancer after radiotherapy. Dis Colon Rectum. 1998; 41: 1488-1493.
156. Engstrom PF, Arnoletti JP, Benson AB, 3rd, et al. NCCN Clinical Practice Guidelines in Oncology. Anal carcinoma. J Natl Compr Canc Netw. 2010; 8: 106-120.
157. Fleshner PR, Chalasani S, Chang GJ, Levien DH, Hyman NH, Buie WD,. Practice parameters for anal squamous neoplasms. Dis Colon Rectum. 2008; 51: 2-9.
158. Welzel G, Hagele V, Wenz F, Mai SK,. Quality of life outcomes in patients with anal cancer after combined radiochemotherapy. Strahlenther Onkol. 2011; 187: 175-182.
159. Rao N, Shridhar R, Hoffe S,. Late effects of pelvic radiation for rectal cancer and implications for survivorship. Semin Colon Rectal Surg. 2014; 25: 38-43.
160. Andersen BL, Anderson B, deProsse C,. Controlled prospective longitudinal study of women with cancer: I. Sexual functioning outcomes. J Consult Clin Psychol. 1989; 57: 683-691.
161. Crook J, Esche B, Futter N,. Effect of pelvic radiotherapy for prostate cancer on bowel, bladder, and sexual function: the patient's perspective. Urology. 1996; 47: 387-394.
162. Das P, Cantor SB, Parker CL, et al. Long-term quality of life after radiotherapy for the treatment of anal cancer. Cancer. 2010; 116: 822-829.
163. Bentzen AG, Balteskard L, Wanderas EH, et al. Impaired health-related quality of life after chemoradiotherapy for anal cancer: late effects in a national cohort of 128 survivors. Acta Oncol. 2013; 52: 736-744.
164. Ferrigno R, Santos A, Martins LC, et al. Comparison of conformal and intensity modulated radiation therapy techniques for treatment of pelvic tumors. Analysis of acute toxicity [serial online]. Radiat Oncol. 2010; 5: 117.
165. Allal AS, Sprangers MA, Laurencet F, Reymond MA, Kurtz JM,. Assessment of long-term quality of life in patients with anal carcinomas treated by radiotherapy with or without chemotherapy. Br J Cancer. 1999; 80: 1588-1594.
166. Bruheim K, Tveit KM, Skovlund E, et al. Sexual function in females after radiotherapy for rectal cancer. Acta Oncol. 2010; 49: 826-832.
167. Lind H, Waldenstrom AC, Dunberger G, et al. Late symptoms in long-term gynaecological cancer survivors after radiation therapy: a population-based cohort study. Br J Cancer. 2011; 105: 737-745.
168. Li M, Fitzgerald P, Rodin G,. Evidence-based treatment of depression in patients with cancer. J Clin Oncol. 2012; 30: 1187-1196.
169. Passik SD, Lundberg JC, Rosenfeld B, et al. Factor analysis of the Zung Self-Rating Depression Scale in a large ambulatory oncology sample. Psychosomatics. 2000; 41: 121-127.
170. Cullen K, Fergus K, Dasgupta T, et al. Toward clinical care guidelines for supporting rehabilitative vaginal dilator use with women recovering from cervical cancer. Support Care Cancer. 2013; 21: 1911-1917.
171. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ,. Cancer statistics, 2007. CA Cancer J Clin. 2007; 57: 43-66.
172. Gwede C, Vadaparampil S, Hoffe S, Quinn G,. The role of radiation oncologists and discussion of fertility preservation in young cancer patients. Pract Radiat Oncol. 2012; 2: 242-247.
173. Andreyev HJ,. Gastrointestinal problems after pelvic radiotherapy: the past, the present and the future. Clin Oncol (R Coll Radiol). 2007; 19: 790-799.
174. Krychman ML, Pereira L, Carter J, Amsterdam A,. Sexual oncology: sexual health issues in women with cancer. Oncology. 2006; 71 (1-2): 18-25.
175. Peltier A, van Velthoven R, Roumeguere T,. Current management of erectile dysfunction after cancer treatment. Curr Opin Oncol. 2009; 21: 303-309.
176. Vaizey CJ, Kamm MA, Turner IC, Nicholls RJ, Woloszko J,. Effects of short term sacral nerve stimulation on anal and rectal function in patients with anal incontinence. Gut. 1999; 44: 407-412.
177. Norderval S, Rydningen M, Lindsetmo RO, Lein D, Vonen B,. Sacral nerve stimulation. Tidsskr Nor Laegeforen. 2011; 131: 1190-1193.
178. Malouf AJ, Vaizey CJ, Nicholls RJ, Kamm MA,. Permanent sacral nerve stimulation for fecal incontinence. Ann Surg. 2000; 232: 143-148.
179. Bennett MH, Feldmeier J, Hampson N, Smee R, Milross C,. Hyperbaric oxygen therapy for late radiation tissue injury [serial online]. Cochrane Database Syst Rev. 2005;(3): CD005005.
180. Gill AL, Bell CN,. Hyperbaric oxygen: its uses, mechanisms of action and outcomes. QJM. 2004; 97: 385-395.